Skip to main content
Adam Boruchov, MD, Hematology, New Milford, CT

AdamMBoruchovMD

Hematology • New Milford, CT

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

SVP, Chair of Cancer Institute, Nuvance Health Professor of Medicine, University of Connecticut SOM

Join to view full profile

Dr. Boruchov is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Boruchov's full profile

Already have an account?

  • Office

    21 Elm St
    New Milford, CT 06776

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 1997

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 2008 - 2025
  • NY State Medical License
    NY State Medical License 1998 - 2010
  • Hematology
    American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Yale Researchers Say Customized Cancer Vaccine Shows Promise
    Yale Researchers Say Customized Cancer Vaccine Shows PromiseMay 20th, 2023
  • Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from Treatment
    Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
  • Nuvance Health Appoints Adam Boruchov, MD, System Chair of the Cancer Institute
    Nuvance Health Appoints Adam Boruchov, MD, System Chair of the Cancer InstituteOctober 26th, 2023

Grant Support

  • Targeting Fcrs On Dcs For Ag-Specific ToleranceNational Institute Of Allergy And Infectious Diseases2005–2008

Professional Memberships

Dr. Adam Boruchov, Dr. Adam Boruchov, MD, Dr. A Boruchov, Dr. Adam M Boruchov